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InhibitorCancer cells which can survive and or proliferate in hypoxia may be resistant to anti-cancer treatment. In our
previous work, we showed that we could group cell lines treated with severe hypoxia into either hypoxia-
induced cell cycle arrest-sensitive or resistant phenotypes, and hypoxia-induced cell death (HCD)-sensitive
or resistant phenotypes. We showed that the resistant phenotypes were associated with high levels of
active-AKT in late hypoxia and sensitive cells were associated with decreased or undetectable levels of AKT
in late hypoxia. We have now extended our ﬁndings to numerous other cell lines. We show that HCD and
loss of AKT is cell density dependent, and both AKT1 and AKT2 isoforms are lost in late hypoxia. Loss of AKT is
most likely due to regulated degradation, as transcription of AKT isoforms is unchanged in hypoxia, and AKT
is not signiﬁcantly translocated to the nucleus to account for its disappearance from cytoplasmic lysates.
Interestingly, inhibitors of proteosome, calpain or caspase-mediated proteolysis did not signiﬁcantly block
AKT loss. Inhibition of autophagy using diverse lysosome-targeted autophagy inhibitors also did not block
AKT loss, however autophagy inhibitors which block general PI3K activity, such as 3-methyladenine or
LY294002, were effective inhibitors of AKT loss in late hypoxia. Interestingly, those inhibitors also blocked
HCD in an HCD-sensitive cancer cell line. Inhibitors of proteolytic pathways which did not block AKT loss also
did not block HCD in HeLa. Our investigations support a model by which AKT is a major switch involved in
regulating hypoxia-induced cell death.ital Dr. N.W., Calgary, Alberta,
82 8727.
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In addition to the shift to an anaerobic metabolism, the normal
cellular response to hypoxia includes cessation of cell division and
apoptosis [1,2]. For many years, the mechanism of hypoxia-mediated
cell death (HCD) was thought to be necrotic, though in some systems
apoptosis could be identiﬁed [3]. More recently, however, hypoxic cell
death was found to exhibit nuclear shrinkage, but caspase-indepen-
dence, and was thought to show an atypical apoptotic mode of cell
death [4]. Lately, it appears that autophagy is likely the main
mechanism of hypoxic cell death [5], at least in some model systems.
Low oxygen tension upregulates several speciﬁc transcription
factors, the most studied of which are the hypoxia-inducible factors
(HIFs) [6]. HIFs facilitate both oxygen delivery and adaptation to
oxygen deprivation by regulating the expression of genes that are
involved in many cellular processes, including glucose uptake and
metabolism, angiogenesis, erythropoiesis, cell proliferation, andapoptosis [7]. The PI-3 kinase pathway has been implicated by others
in altering levels of HIF-1α (e.g.[8]). This pathway is activated by PI-3
kinase (PI3K) and is one of the major positive regulatory pathways of
proliferation and negative regulatory pathway of apoptosis in the cell
[9]. A major downstream target of this pathway is the survival protein
kinase Protein Kinase B/AKT.
AKT, consisting of 3 closely related isoforms in human, is involved
in cellular survival pathways by inhibiting apoptotic processes [10].
AKT possesses a protein domain, known as a PH (Pleckstrin
Homology) domain, which binds to phosphoinositides. Binding of
PIP3 to the PH domain results in translocation of AKT/PKB to the
plasma membrane where it is activated by phosphorylation by
upstream kinases including the phosphoinositide-dependent kinase
1 (PDK1). PDK1 phosphorylates Thr308 of membrane-bound AKT and
Ser473 is phosphorylated by mTORC2. It has been thought by most
investigators that both kinase sites (Thr308 and Ser473) must be
phosphorylated for AKT to be active [11]. Dephosphorylation of these
residues is attributed to PP2A. Downstream targets of AKT are
regulators of various cell survival pathways and include glycogen
synthase kinase 3 β (GSK3β), TSC2 protein (downregulator of the
kinase mTOR, which regulates S6 kinase (S6K) and translation) and
several growth regulating transcription factors including the cell cycle
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downstream kinase mTOR also participates in the activation of AKT as
a component of the PDK2/mTORC2 complex [12].
AKT is directly involved in downregulating apoptosis [13] by virtue
of its downregulation of a variety of pro-apoptotic proteins such as
BAD or the Forkhead transcription factors (FOXO1, FOXO2, FOXO3)
[14]. AKT can also directly inhibit apoptosis by blocking cytochrome c
[15]. Interestingly, AKT is also found to regulate autophagy [16]. As it
appears that hypoxic cell death may occur via autophagy [5], the
regulation of both autophagy and apoptosis by AKT is interesting. The
function of speciﬁc AKT isoforms has only recently been the focus of
much study. Knockout of speciﬁc AKT isoforms can initiate apoptosis
in a variety of epithelial cell lines but the phenotype is cell type
speciﬁc [17]. The speciﬁcity of AKT isoform is important in thymocyte
differentiation [18] and in myocyte differentiation [19]. Thus, through
its interface with several important growth and/or apoptosis
regulatory pathways, AKT has a primary function in regulating cell
survival in the face of a wide variety of stressful or toxic stimuli, but
the expression and function of the different AKT isoforms is often cell
type speciﬁc.
Our previous work initially focused on the effect of hypoxia on cell
cycle regulation. We identiﬁed cell lines which either did or did not
exhibit a cell cycle arrest phenotype in response to severe hypoxia
[20]. We found a correlation between the decrease of several
regulatory proteins, including AKT, in late hypoxia and the cell cycle
arrest phenotype. Cells which showed an arrest phenotype exhibited
a loss of total AKT and other proteins at 12 h of hypoxia. Cells which
did not show the arrest phenotype did not exhibit loss of AKT or many
of the other proteins. Further investigations showed that cell cycle
arresting cells also eventually underwent cell death, which was
initiated following approximately 12 h of hypoxia treatment, with a
perfect correlation between loss of AKT protein and/or AKT activity
and cell death [21].
We have hypothesized that AKT may be a major switch
regulating cell death in epithelial cells. If AKT activity is lost at
around 12 h following hypoxia treatment, cells may be destined to
undergo hypoxia-induced cell death (HCD). Cells in which AKT
activity was not lost were destined to survive. In this study, we
seek to show further support for our hypothesis by studying
additional cell types treated with severe hypoxia, and investigating
potential mechanisms by which AKT can be downregulated in
severe hypoxia.
2. Materials and methods
2.1. Reagents
For this study, the following reagents were used: MG132, BOC-D-
FMK, 3-methyladenine, EHNA, baﬁlomycin A1, NH4Cl, chloroquine,
methylamine, LY294002, rapamycin, desferroxamine, 0.4% Trypan
blue solution (Sigma-Aldrich); Calpeptin, ALLM and ALLN (EMD
Biosciences); TRIzol LS (Invitrogen). The constitutively active AKT
mutant (CA-AKT) was a generous gift of the Hemmings laboratory
[22].
2.2. Tissue culture
HeLa (cervical carcinoma) cells were cultured in DMEM (Invitro-
gen) supplemented with 10% FBS and incubated at 5% CO2/37 °C for
48 h to 30–80% conﬂuency prior to exposure to hypoxic conditions.
Hypoxia was established by incubating cells in the GasPak anaerobic
incubator (BD Bioscience), which reduces O2 levels while maintaining
CO2 levels at approximately 5%. O2 levels were monitored by a
methylene blue indicator strip, which bleaches white at 0.1–0.5% O2
levels, following which timing of hypoxia was measured. For titration
of O2 levels, cells were placed in a Billup-Rothenberg hypoxiachamber. The chamber was then ﬂushed with 20 L/min for 5 min of
the appropriate O2 gas, balancedwith 5% CO2 / 95% N2. O2 levels in the
chamber were monitored using a polaragraphic O2 sensor (Billup-
Rothenberg). Untreated controls were incubated alongside hypoxic
samples under a normal tissue culture gas mixture (20% O2/ 5% CO2).
Desferroxamine (DFX) treated cells were cultured as above and
incubated in a 260-µM ﬁnal concentration of DFX for the indicated
time points. Untreated cells were incubated in identical conditions,
with the addition of an equal (200 µl) volume of PBS as an untreated
control.
2.3. Protein isolation from tissue culture
HeLa cells were cultured as indicated previously. All steps were
performed on ice (0 °C), unless otherwise noted. Tissue culture media
was removed and the cells rinsed with 10 ml of ice cold 1× PBS
(137 mM NaCl, 10 mM Phosphate, 2.7 mM KCl, pH 7.4). After rinsing,
the PBS was removed and the plate tilted to the side to allow for
maximal removal of residual PBS. For a 150 mm tissue culture dish,
400 µl of NP-40 lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 10%
glycerol, 1.5 mM MgCl2, 1 mM EGTA, 100 mM NaF, 1% NP-40, 10 µM
sodium vanadate, 10 µM PMSF, 10 µg/ml aprotinin, 5 µg/ml leupep-
tin) were added and the cells scraped down using a disposable rubber
spatula (Sarstedt). Cell nuclei were extracted using a commercial
nucleus isolation kit (Sigma) according to manufacturer's protocol.
Whole cell protein and nuclear protein were prepared by nuclei lysis
buffer (50 mM Tris pH 7.5, 0.5 M NaCl, 1% NP-40, 1% DOC, 0.1% SDS,
2 mM EDTA, 10 µM sodium vanadate, 10 µM PMSF, 10 µg/ml
aprotinin, 5 µg/ml leupeptin). The cell lysates were transferred to a
new, prechilled 1.5 ml tube and incubated for 15 min. After
incubation, the DNA was sheared by passing the lysate through a
21G needle 10 times and insoluble material was removed by
centrifugation for 10 min at 14,000g at 4 °C. Protein lysates were
stored at −80 °C until needed.
2.4. Western blot
Determination of protein concentration, Western blotting, and
immunodetection were performed as described previously [20], with
the exception that 40 µg per lane of lysate was loaded onto SDS-PAGE
gels. For immunodetection, the following antibodies were used: AKT
(#9272, 1:2000), AKT1 (#2967, 1:1000), AKT2 (#2964, 1:1000),
phospho-AKT (Thr308) (#9275, 1:1000), phospho-AKT (Ser473)
(#9271, 1:1000), phospho-GSK3β (Ser9) (#9336, 1:2000) (Cell Signal
Technology); HIF-1a (#610959, 1:1000), GSK3β (#610201, 1/2000),
pan Actin (MS-1295-P1, 1:2000), (Neomarkers); a-tubulin (sc-53646,
1: 400), Lamin A/C (sc-7292, 1:400), SQSTM1/p62 (sc-28359, 1:400)
(Santa Cruz Biotechnology).
2.5. Determination of cell viability
HeLa cells were seeded in DMEM and cultured for 48 h prior to
hypoxia treatment in absence or presence of different inhibitors.
Floating and adherent cells were collected at 0 h, 6 h or 24 h, spun
down and resuspended in the corresponding cell media. Cells were
then diluted 1:1 with 0.4% Trypan blue solution (Sigma Chemical Co.)
for 2 min and scored under a phase contrast microscope using an
improved Neubauer-Levy hemacytometer (Hausser Scientiﬁc). Cell
viabilitywas calculated as follows: %viability=(unstained cell count/
total cell count)×100; dead cell %=(stained cell count/total cell
count)×100.
2.6. RNA extraction
Total cellular RNA was isolated using TRIzol agent according to
manufacturer's protocol, which was modiﬁed as follows: RNA was
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0.8 M sodium citrate, to prevent proteoglycan contamination. RNA
was re-suspended in DEPC-treated H2O, quantiﬁed, and used
immediately or precipitated and then stored in 100% ethanol at
−80 °C for later use.
2.7. Semi-quantitative RT-PCR
After isolation and quantiﬁcation of RNA, ﬁrst strand cDNA
synthesis was performed by Superscript II Reverse Transcriptase
(Invitrogen) according to manufacturer's protocol. The products were
used as the template for PCR reactions. The primers used were AKT1
(PCR product of 375 bp), forward-AGCCTGGGTCAAAGAAGTCA, re-
verse-AGGTGCCATCATTCTTGAGG; AKT2 (PCR product of 303 bp),
forward-GGCTCCTTCATTGGGTACAA, reverse-AGTCGTGGAGGAGT-
CACTGG; 28 S rRNA (PCR product of 453 bp), forward-GACG-
CACCCCCGCCACGCAGTTTT, reverse-CCGCCGCCCTCCGACGCACAC.
28 S rRNA PCR was performed to control for loading and initial RNA
quantity. 100 ng of cDNA from untreated (UT) or treated (T) samples
were placed in a Biometra thermal cycler and subjected to varying
number of PCR cycles (20, 25, 30 or 35) under annealing temperature
optimized conditions with a speciﬁc cDNA exon-spanning primer set
in order to identify amplicons prior to the plateau phase of
ampliﬁcation. All PCRs were performed using the following program:
95 °C for 2 min, 95 °C for 1 min, 60 °C for 30 s and 72 °C for 2 min.
Cycle number was determined as mentioned above and a ﬁnal
extension at 72 °C for 10 min was utilized. PCR products were
analyzed by agarose gel electrophoresis and visualized by ethidium
bromide staining.
2.8. Microarray
cDNA synthesis and labelling for microarray was performed using
the FairPlay II Microarray Labeling Kit (Stratagene) according to
manufacturer's protocol. The cDNA pellet was labelledwith 5 µl of Cy3
or Cy5 CyDye™ mono-Reactive Dye (Amersham-Pharmacia) and the
labelled cDNA-hybridization was performed by DIG Easy Hyb solution
(Roche) according to manufacturer's protocol. Microarray data were
generated by the Southern Alberta Microarray Facility (SAMF).
3. Results
We have previously reported loss of total AKT in HeLa cells treated
with severe hypoxia occurring approximately 12 h following the
onset of hypoxia and very near, or slightly preceding cell death. It was
also shown that human mammary epithelial cells exhibited signiﬁ-
cant cell death and functional loss of AKT as shown by the absence of
phosphoSer21-GSK3β after 24 h in hypoxia [21]. Cell death could be
equally measured using ﬂow cytometry/Annexin V-staining or simple
Trypan Blue dye staining.
We sought to show additional support for our earlier results by
extending our ﬁndings to other human cell models. Fig. 1 shows that
breast cancer cell lines HTB30, HTB130 and HTB132 exhibited no
measurable loss of AKT and no signiﬁcant cell death after 24 h of
severe hypoxia treatment, similar to the HCD-resistant phenotype of
Hep3B cells, a well characterized model in hypoxia research which we
have previously shown to exhibit both hypoxia-induced cell cycle
arrest and HCD-resistant phenotypes. The phospho-GSK3β protein
levels in panel B shows that AKT kinase activity is not lost in the three
cell lines in late hypoxia.
Furthermore, we tested several other cell lines derived from
different origins for AKT loss and HCD phenotype (Fig. 2). 293 T
(human embryonic kidney epithelial), HTB125 (human mammary
gland ﬁbroblast), WI38 (human lung ﬁbroblast) and HaCat (human
keratinocyte) cells were cultured in normoxia or hypoxia for 6 or 24 h
and evaluated for viability and AKT expression. The cell line 293 Tshowed a similar result to the HCD-sensitive cell line, HeLa with high
cell death and low AKT levels after 24 h of hypoxia treatment, while
the other cells showed an HCD-resistant phenotype of low cell death
with no loss of AKT levels.
In these experiments, HeLa loses almost all cytoplasmically
detectable total AKT proteins, however, we could occasionally observe
subtotal loss of AKT or, rarely, AKT proteins were not lost at all
(unpublished observations) with no recognized technical problem or
other possible explanation. As cell density has been shown by others
to affect HIF-1α regulation [23], we investigated the effect of cell
density on AKT loss in HeLa cells treated with severe hypoxia to
determine if variability in inoculum was responsible for variability in
AKT loss. Fig. 3 shows titrations of HeLa cells added to tissue culture
dishes approximately 48 h prior to hypoxia treatment. These titra-
tions yielded ﬁnal conﬂuency of between 10% and 80% at the initiation
of hypoxia treatment, depending on starting inoculum size. Our
results clearly show that the initial cell density signiﬁcantly affected
the levels of total AKT protein found after 24 h of severe hypoxia
treatment. The threshold for loss of HIF-1α was somewhat greater
than loss of AKT, though, as the seeding of 0.5×106 HeLa cells
followed 24 h later by hypoxia treatment was sufﬁcient to result in
loss of detection of HIF-1α but not total AKT proteins. The levels of
pSer473-AKT and pThr308-AKT correlated with the levels of total AKT
proteins at all HeLa densities. Our subsequent work (not shown)
identiﬁed that maintaining a ﬁnal conﬂuency of at least 70–80% prior
to hypoxia treatment was more important than the initial cell
inoculum. We tightly maintain a practice of transferring 4×106 cells
into 20 ml of medium onto a 150-mm tissue culture dish and allowing
growth to ∼80% conﬂuency (N24 h, which also serves to negate the
metabolic stimulus of fresh serum) before hypoxia treatment in all
subsequent experiments.
Having identiﬁed an important variable to the phenomenon of loss
of detection of all AKT isoforms, we decided to investigate the isoform
speciﬁc expression of AKT in HeLa, as well as the kinetics of isoform
expression in hypoxia. Fig. 4 shows our standardized treatment of
HeLa cells for 6, 12 or 24 h of hypoxia followed by Western blotting
with AKT isoform 1 and 2-speciﬁc antibodies. We chose not to
evaluate AKT3 protein expression, as it has been reported to be
expressed in a tissue speciﬁc manner [24]. The results show that both
major AKT isoforms are expressed in HeLa and are lost in late hypoxia,
though AKT2 appears to be lost earlier than AKT1.
Since total AKT protein levels were signiﬁcantly decreased in late
hypoxia, the mechanism by which this was achieved in the cell was of
considerable interest. Loss of expression of proteins such as AKTs
could be due to decreased transcription of short-lived proteins,
decreased translation of short-lived proteins, intracellular compart-
mentalization of proteins outside of our cytoplasmic extracts, or
increased turnover/degradation of the proteins. Previous literature
suggested that AKT/PKB proteins had reasonably long intracellular
half lives, and were primarily regulated by phosphorylation status,
arguing against the ﬁrst two proposed mechanisms, but we chose to
evaluate the kinetics of AKT mRNA expression in diverse cell lines.
Fig. 5A shows the average expression levels of the three different AKT
isoforms in HeLa treated with either desferroxamine or severe
hypoxia. As can be seen, the levels do not change signiﬁcantly over
the 24 h of either treatment. DFX-treated HeLa cells did not express
high enough levels of AKT2 to pass the weak-spot threshold for any
time point, as was also observed with the 24-h time point for AKT2
expression in HeLa cells. Independent, semi-quantitative analysis of
AKT transcripts shown in Fig. 5B conﬁrms the lack of speciﬁc
downregulation observed in the microarray results. In HeLa, AKT
isoform-speciﬁc transcript levels do not appear to explain the drop in
protein levels.
For our typical evaluation of HeLa proteins, we used a cell lysis
buffer containing NP-40 detergent, which is known to be poor at
permeabilizing nuclei. Since it was possible that AKT could be
Fig. 1. Hypoxia-induced cell death phenotypes of breast epithelial cells. Panel A, HTB30, HTB130, or HTB132 cells were incubated in normoxia (20% O2, UT) or hypoxia (b0.5% O2, T)
for the indicated times. Cells were incubated with an equal volume of 0.4% Trypan blue stain for 2 min. Cells were then counted on an improved Neubauer-Levy hemacytometer and
the percent viability was determined. (n=3, SEM). Panel B, HTB30, HTB130, or HTB132 cells were exposed to normoxia (20% O2, UT) or hypoxia (b0.5% O2, T) and used to prepare
total cell lysates. 40 µg/lane of protein extracts were run out on an 8% SDS-PAGE gels and transferred to PVDF membrane. Membranes were then blotted for phospho-AKT, total AKT,
phospho-GSK3β, or total GSK3β as before.
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extraction with NP-40 lysis buffer, we evaluated nuclear versus
cytoplasmic localization of AKT protein during our hypoxic treatment
of HeLa cells. Fig. 6 shows that almost all of the AKT in HeLa cells is
cytoplasmic, and that there is no signiﬁcant shift of AKT proteins into
the nucleus in late hypoxia. This result, in addition to the transcript
expression data leads to the conclusion that AKT proteins are most
likely degraded in the hypoxic response.
Some initial experiments evaluated the effect of a subset of
inhibitors of proteosomal degradation on AKT protein expression inlate hypoxia [21]. These experiments suggested that proteosome
inhibitors, MG132 and β-lactacystin, and caspase inhibitor Boc-D-fmk
were ineffective at preventing loss of AKT proteins but inhibited the
loss of other proteins known to undergo regulated degradation.
Similarly, Fig. 7 shows that calpain inhibitors ALLM, ALLN and
Calpeptin used at concentrations much higher than used by others
[25,26]were also not sufﬁcient to abrogate the loss of AKT protein as
detected by Western blotting in hypoxia-treated HeLa cells.
Our experiments to determine the cellular mechanism for the loss
of total AKT proteins using inhibitors thus led to the unexpected
Fig. 2. Evaluation of additional cell lines for AKT loss and survival in severe hypoxia. Panel A, Cell lines, as indicated, were exposed to normoxia (hypoxia 0 h) or hypoxia for 6 or 24 h.
Three separate aliquots of pooled of adherent and suspension cells were counted using Trypan blue to identify “dead” cells. A histogram of non-viable cells for the various cell lines is
shown with standard errors as noted by error bars. Panel B, 40 µg of total cell lysates of the treated cells were run out on an 8% SDS-PAGE gel and transferred to a PVDF membrane.
The membrane was blotted for total AKT. Actin blots were also performed to ensure the loading of equal amounts of protein.
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seemed to mediate the loss of AKT. A major proteolytic pathway that
we did not investigate involves lysosomal proteases, and could be
inhibited at several levels. As autophagy is mediated by lysosomal
proteolysis, and autophagy has been shown to be a signiﬁcant
mechanism for HCD, this pathway would be an obvious candidate
for degradation of AKT in late hypoxia, near the onset of HCD. Fig. 8
shows our results from the use of several different autophagy/
lysosome-mediated degradation inhibitors. Clearly baﬁlomycin A1,
chloroquine, ammonium chloride and methylamine did not abrogate
the loss of AKT observed in late hypoxia. These compounds are all
suggested to inhibit lysosome-mediated proteolytic events via diverse
mechanisms [27]. EHNA, which is a potent inhibitor of adenine
deaminase also blocks dynein-mediated protein transport through
microtubules and autophagosome formation [28], did not block AKT
loss at even high concentrations, though it also showed weak activity
in preventing the loss of the autophagy-degraded control protein, p62
[29].
3-methyladenine (3-MA) whose known function is to inhibit class
III PI3-kinases, activation of which is important in autophagy [27],
almost completely blocked the loss of AKT proteins. As it seemed clear
that blocking autophagy through inhibition of autophagosomeFig. 3. Effect of plating cell density on hypoxia-related loss of AKT and pAKT. HeLa cells were
media/150 mm tissue culture plate) for the times indicated (0, 6, 12, 24 h treated). Final co
cells) and N95% (4X106 cells). 40 µg/lane of protein extracts were run out on an 8% acrylam
total AKT, phospho-AKT (Thr308), phospho-AKT (Ser473), HIF-1α and actin. Actin blots wereformation or lysosomal proteolysis did not block loss of AKT, it was
likely that the protective function of 3-MA was exerted through its
PI3K inhibitory functions.
To test this, we evaluated the effect of another inhibitor of PI3K
signaling on AKT loss in late hypoxia. Fig. 9 shows that the class I PI3K
inhibitor, LY294002 signiﬁcantly blocked loss of AKT in late hypoxia,
similar to the effect of 3-MA. Interestingly, much less, but discernable,
protection was afforded by rapamycin and 100 uM ALLN. As we
hypothesize that loss of AKT serves to initiate HCD, we tested the
effect on HCD of the various proteolysis inhibitors. Fig. 10 shows the
effect of diverse inhibitors on HCD in the HCD-sensitive cell line, HeLa.
While many proteolysis inhibitors (other than EHNA) may have
offered a slight increase in cell survival, a large decrease in HCD was
observedwhen HeLawas treatedwith 3-MA and LY294002—the same
two inhibitors that protect against AKT loss.
4. Discussion
We have previously described loss of AKT activity and, almost
always, AKT protein levels in late hypoxia, in HCD-sensitive cells
however, the mechanism for this decrease in function and protein
levels is unknown. We undertook further studies to betterplated at varying densities for 48 h prior to hypoxia treatment (cell number per 20 ml
nﬂuency prior to harvesting cells was approximately 30% (0.5×106 cells), 60% (2×106
ide SDS-PAGE gels and transferred to PVDF membrane. The membrane was blotted for
also performed to ensure the loading of equal amounts of protein.
Fig. 4. AKT isoform protein expression in late hypoxia. HeLa cells were incubated in
normoxia (20% O2, UT) or hypoxia (b0.5% O2, T) for the indicated times then lysed.
40 µg/lane of protein extracts were run out on an 8% acrylamide SDS-PAGE gels and
transferred to PVDF membrane. The membrane was blotted for AKT1, AKT2, total AKT
and actin. Actin blots were also performed to ensure the loading of equal amounts of
protein.
Fig. 6. Intracellular localization of AKT in hypoxia. HeLa cells were exposed to normoxia
(hypoxia, 0 h) or hypoxia for 6 or 24 h. Cell lysates were prepared for whole cell,
cytoplasmic or nuclear protein using reagents from a commercial intracellular
compartment lysis kit and nuclear lysis buffer. 40 µg/lane of protein extracts were
run out on an 8% acrylamide SDS-PAGE gels and transferred to PVDF membrane.
The membrane was blotted for total AKT, nuclear lamins (nuclear protein control) and
α-tubulin (cytoplasmic protein control).
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tion is not signiﬁcantly downregulated in hypoxia. It is known that
there is a general decrease in translation associated with hypoxia [30],
and this seems to occur in a HIF-1-independent manner, perhaps
regulated by the AKT-downstream kinase, mTOR but in an AKT-
independent manner [31,32]. However, it is difﬁcult to reconcile
translational downregulation of AKT as the rationale for its sudden
disappearance after 12–24 h of hypoxia treatment when it has been
noted to have a 36-h half life [33]. We have also dismissed another
potential mechanism accounting for rapid loss of AKT by showing that
AKT is not sequestered in the nucleus as a mechanism accounting for
its loss from cytoplasmic extracts. By far the most likely mechanism to
account for the reasonably sudden decreased levels of AKT that we
observed in correlation with sensitivity to HCD is degradation. As
many soluble cellular proteins that we measured, such as GSK3ß, areFig. 5. Expression of AKT genes in the hypoxic response. Panel A, HeLa cells were treated
with hypoxia or DFX for 6, 12 and 24 h then the total RNA was evaluated by expression
proﬁling using University of Calgary 14 K microarray chips. Following elimination of
weak spots, the treated/untreated ratios were converted to log2 values and normalized
by LOWESS. Mean Log2 expression is plotted with time of hypoxia treatment for each
isoform in hours. Panel B, 5 µg of total cellular RNA were used to generate cDNA. Semi-
quantitative RT-PCR of AKT1 and AKT2was performedwith speciﬁc PCR primer sets, using
100 ng of cDNA in a total PCR master mix volume of 25 µl. PCRs were evaluated on a 0.8%
agarose gel. PCR for 28 S rRNA was performed to indicate equal initial cDNA quantities.
HeLa cells were incubated with normoxia (20% O2, UT) or hypoxia (b0.5% O2, T) for the
indicated times.not lost in hypoxia, degradation of AKT was likely speciﬁc and
regulated. Supporting this conclusion, we have sometimes noticed
(though not in all experiments) that as AKT levels start to decrease in
late hypoxia (samples at 12 or 24 h) lower molecular weight bands
reacting with the anti-total AKT antibody start to appear. We have
never investigated these, but have commented on them in our papers
[21]. Others have also noticed this phenomenon [12,34]. The multiple
bands detected with anti-panAKT antibodies may represent degraded
AKT proteins, or simultaneous expression of the different AKT
isoforms which differ slightly in molecular weight/mobility [35], or
their phosphorylated isoforms [36]. They could also indicate different
forms of ubiquitinylated AKT, recently described as an alternately
activated form of AKT [37].
Surprisingly, degradation of the AKT kinases has not been a subject
of much investigation to date. The earliest report demonstrated that
AKT could be cleaved in a fas-stimulated apoptosis model system by a
caspase-dependent mechanism [38]. Occasional subsequent reports
have described the degradation of AKT in response to diverse stimuli,
such as platelet derived growth factor, insulin like growth factor-1,
and TNF-α [39,40]. Cisplatin and daunorubicin were found to induce
AKT cleavage through activated caspases [41,42]. Likewise, AKT was
found to be a caspase target in glioblastoma cells treated with VP16
[43]. Loss of AKT initiated through the VEGF pathway was found to be
inhibited by broad-spectrum inhibitors of caspases and proteosomal
degradation [44]. Additionally, degradation of AKT in response to
H2O2 induced apoptosis has also been reported [45]. This seemed to be
mediated by a caspase, but the speciﬁc protease could not be deﬁned.
Thus, it seems that degradation of AKT is regulated in other contexts
than hypoxia, and the few reports describing the phenomenon reveal
diverse mechanisms of proteolysis.
In hypoxia, most investigators feel that AKT is upregulated (e.g.
[46]) and, other than us, have not thoroughly evaluated its regulation
in severe hypoxia and/or extended hypoxia models. The overall
reduction of AKT activity in hypoxia has signiﬁcant implications for
the cell. AKT activation in hypoxia has been hypothesized as anti-
apoptotic [47], downregulating pro-apoptosis proteins such as BAD
[48]. AKT activation reduced cardiac myocyte apoptosis in models of
ischemia [49]. AKT may also inhibit cell death caused by autophagy as
well, since PTENmediated inhibition of AKT and use of an AKT speciﬁcFig. 7. Effects of proteolysis inhibitors on AKT Levels in HeLa cells treated with severe
hypoxia. HeLa cells were exposed to normoxia or hypoxia for 24 h. Cells were treated
with calpain inhibitors ALLN, ALLM and Calpeptin at the indicated concentrations
starting 1 h before hypoxic exposure. 40 µg of total cell lysates were run out on an 8%
SDS-PAGE gel and transferred to a PVDF membrane. The membrane was blotted for
total AKT and actin. Actin blots were also performed to ensure the loading of equal
amounts of protein.
Fig. 8. Effects of autophagy inhibitors on AKT levels in HeLa cells treated with severe hypoxia. HeLa cells were exposed to normoxia (hypoxia 0 h) or hypoxia for 6 or 24 h. Cells were
treated with a panel of autophagy inhibitors at the indicated concentrations starting 1 h before hypoxic exposure. 40 µg of total cell lysates were run out on an 8% SDS-PAGE gel and
transferred to a PVDF membrane. The membrane was blotted for total AKT, p62 (autophagy proteolysis control) and actin. Actin blots were also performed to ensure the loading of
equal amounts of protein. Panel A shows no effect of Erythro-9-[3-(2-hydroxynonyl)] adenine (EHNA) at two concentrations and baﬁlomycin A1 (Baf.A1)while 3-methyladenine (3-
MA) decreases loss of AKT and p62. Panel B shows a similar experiment using three additional autophagy inhibitors (ammonium chloride, chloroquine and methylamine).
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initial increase in AKT phosphorylation in hypoxia may be an initial
survival signal of the cells. The reduction of AKT protein that we
observe in hypoxia might potentiate already present apoptotic
signals. Recent literature supports this idea, since depletion of AKT
by RNAi has been found to promote apoptosis in hypoxia-treated
neuroblastoma cells [52]. As well, reduction of AKT levels in diverse
cancer cell lines demonstrates that signiﬁcant loss of one or more AKT
isoforms in some cells is lethal [17].
Loss of HIF-1α and cyclin D1 is known to occur in a proteosome-
dependent manner in hypoxia [53], suggesting that hypoxia-regulat-
ed degradation of AKT may also occur. Loss of some proteins, such as
SQSTM1/p62 in hypoxia is known to be mediated by autophagy [29].
We and others have detected the loss of several other proteins in late
hypoxia, however, this is a speciﬁc event as our data show that many
other cellular proteins such as actin, PARP, and GSK3β are not lost in
late hypoxia. Assuming that the degradation of AKT was regulated
conventionally, we evaluated the roles of diverse protein degradation
pathways on the loss of AKT in late hypoxia. Our experiments with
inhibitors of proteosomal degradation, caspases, calpains and ﬁnally
lysosomal proteolysis did not identify any of these pathways as
individually, mediating the majority of the loss of AKT that we
observed. Interestingly, we did ﬁnd that inhibition of either class I or
class III PI3-kinases was associated with stabilization of AKT levels in
late hypoxia, and signiﬁcantly increased HeLa survival in hypoxia.
How these compounds exert their effect on AKT, independent to theirFig. 9. Effects of PI3K, mTOR, calpain or autophagy inhibitors on total AKT and p62 levels
in HeLa cells treated with severe hypoxia. HeLa cells were exposed to normoxia
(hypoxia 0 h) or hypoxia for 24 h. Cells were treated with a panel of signaling or
autophagy inhibitors at the indicated concentrations starting 1 h before hypoxic
exposure. 40 µg of total cell lysates were run out on an 8% SDS-PAGE gel and transferred
to a PVDF membrane. The membrane was blotted for total AKT, p62 (autophagy
proteolysis control). Actin blots were also performed to ensure the loading of equal
amounts of protein.inhibition of autophagy, is unknown and could indicate an interesting
newmode of AKT regulation. Perhaps AKT activity/phosphorylation is
the inducer, as PI3-K signaling certainly mediates these effects?
Reduced AKT function through protein loss may represent a
commitment of the cell to HCD. The initial activation of AKT in
hypoxia has been well described in the literature (e.g.[54]) and
hypoxic preconditioning of cells has been shown to impart a
signiﬁcant survival advantage during a subsequent ischemic event
(e.g.[55]). Work by several investigators has shown that upregulation
of several pro-apoptotic transcripts through HIF-1 occurs in hypoxia
[56,57]. These transcripts are usually expressed early in the hypoxic
response of many cell lines however, many cell lines do not undergo
hypoxia-mediated cell death in spite of upregulation of pro-apoptotic
genes. Plainly, just expressing these transcripts and proteins may not
be sufﬁcient for cell death. Interestingly, several of these proteins have
consensus AKT kinase sites, including BNIP3L and NDRG1. Therefore,
elimination of the AKT signaling network may be critical in regulating
HCD associated with these pro-apoptotic proteins. Theoretically, if the
hypoxic exposure was not severe or protracted, AKT signaling could
ensure survival long enough for metabolic adaptation and alleviation
of low O2 levels through angiogenesis. This concept is reinforced by
the fact that AKT signaling will enhance HIF-1 protein levels and
increase the hypoxic transcriptional response [58]. If the hypoxic
growth conditions became overwhelming, removal of AKT signaling
would abrogate its potent anti-apoptotic effects and allow for cell
death to occur. It has been shown by others that a signiﬁcantly
reduced level of O2 is essential for hypoxia-induced cell death [59].
High cell densities may more rapidly and severely reduce O2 levels in
tissue culture media [60], and in our model would be expected to
result in earlier triggering of the AKT loss and, perhaps, cell death
which we observed.
Our current and previous work supports a model where functional
levels of AKT may regulate the HCD response. Perhaps there is a
decision point, similar to the RB phosphorylation event at the G1
restriction point, “R,”where AKT becomes inactivated by degradation
or other modes of inactivation, contributing to overbalance by pro-
apoptotic proteins and subsequent cell death. Preservation of AKT
levels in late hypoxia protects HCD-sensitive cells from HCD. The
mechanism of the loss of AKT proteins in late hypoxia is still not fully
elucidated, though appears to be as a result of protein degradation by
a non-typical pathway, and is dependent on PI3K activation, but not
lysosomal proteolysis.
Fig. 10. Effects of proteolysis inhibitors on survival of HeLa cells treated with severe hypoxia. HeLa cells were exposed to normoxia (0HT) or hypoxia for 24 h. Cells were treated with
a panel of proteolysis inhibitors (50 µM LY294002, 10 µM rapamycin, 100 µM ALLN, 50 µM Boc D fmk, 100 µM MG132, 20 mM 3-MA, 50 µM EHNA, 150 nM baﬁlomycin A1, 20 mM
NH4Cl, 10 mMmethylamine, 100 uM chloroquine) starting 1 h before hypoxic exposure. Three separate aliquots of pooled of adherent and suspension cells were counted using 0.4%
Trypan blue to identify “dead” cells. A histogram of non-viable cells for the various treatments is shownwith standard errors as noted by error bars. 40 µg of total cell lysates were run
out on an 8% SDS-PAGE gel and transferred to a PVDFmembrane. The membrane was blotted for total AKT and actin (actin not shown for brevity). Western blot results show the AKT
levels for each treatment of proteolysis inhibitors, under the corresponding treatment column of the histogram.
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